Bcl-2 inhibition sensitizes triple-negative human breast cancer cells to doxorubicin.

Inao, Touko; Iida, Yuichi; Moritani, Tamami; Okimoto, Tamio; Tanino, Ryosuke; Kotani, Hitoshi; Harada, Mamoru

Inao, Touko; Iida, Yuichi; Moritani, Tamami; Okimoto, Tamio; Tanino, Ryosuke; Kotani, Hitoshi; Harada, Mamoru.

Afiliación

Inao T; Department of Immunology, Shimane University Faculty of Medicine, Shimane, Japan.
Iida Y; Department of Breast Surgery, Takasago City Hospital, Hyogo, Japan.
Moritani T; Department of Immunology, Shimane University Faculty of Medicine, Shimane, Japan.
Okimoto T; Department of Immunology, Shimane University Faculty of Medicine, Shimane, Japan.
Tanino R; Division of Medical Oncology & Respiratory Medicine, Department of Internal Medicine, Shimane University Faculty of Medicine, Shimane, Japan.
Kotani H; Division of Medical Oncology & Respiratory Medicine, Department of Internal Medicine, Shimane University Faculty of Medicine, Shimane, Japan.
Harada M; Department of Immunology, Shimane University Faculty of Medicine, Shimane, Japan.

Oncotarget ; 9(39): 25545-25556, 2018 May 22.

Article en En | MEDLINE | ID: mdl-29876007

Palabras clave

ABT-199; Bcl-2; breast cancer; doxorubicin; triple-negative

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Idioma: En Revista: Oncotarget Año: 2018 Tipo del documento: Article País de afiliación: Japón

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google